Ionis Pharmaceuticals: EVP Shannon L. Devers sold 1,357 shares

What happened

• Shannon L. Devers, EVP and chief human resources officer, acquired 2,820 shares on Oct 15, 2026 pursuant to vesting and release of restricted stock units and immediately had a derivative conversion recorded. On Oct 16, 2026 she sold 1,357 shares in the open market at a weighted average price of $43.54, for proceeds of $59,082.

Key details

• Transaction dates and prices:
  • Oct 15, 2026: exercise/conversion of derivative (M) — 2,820 shares @ $0.00 (acquired) (F1, F4, F5).
  • Oct 15, 2026: exercise/conversion of derivative (M) — 2,820 shares @ $0.00 (disposed) (derivative conversion reported).
  • Oct 16, 2026: open market sale (S) — 1,357 shares @ weighted average $43.54, proceeds $59,082; per the filing sale prices ranged from $43.1383 to $43.538918 (F2, F3).
• Shares owned after the transaction: not specified in the filing.
• Relevant footnotes: shares were acquired via RSU vesting and release (F1); the Oct 16 sale was an automatic sale to cover tax withholding obligations under the RSU agreement (F2); the filing reports a weighted average price and a per-share price range (F3); each RSU represents a contingent right to one share (F4); RSUs vest in four equal annual installments and are paid in shares or cash as determined by the company (F5).
• Filing information: Form filed Oct 19, 2026 covering transactions with period ending Oct 15, 2026.

Why it may matter

• The filing shows RSUs vested and shares were issued, with a portion sold via an automatic tax-withholding sale rather than a discretionary open-market decision.
• The filing does not show why the insider traded or why the company acted.